Century Therapeutics/$IPSC
1D1W1MYTD1Y5YMAX
Capital at risk
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
- Ticker
- $IPSC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 78
- Headquarters
- Philadelphia, United States
- Website
- www.centurytx.com
IPSC Metrics
BasicAdvanced
$335M
-
-$0.77
1.60
-
Price and volume
Market cap
$335M
Beta
1.6
52-week high
$3.04
52-week low
$0.44
Average daily volume
464K
Financial strength
Current ratio
8.28
Quick ratio
8.043
Long term debt to equity
0.149
Total debt to equity
0.166
Profitability
EBITDA (TTM)
-95.223
Effective tax rate (TTM)
0.06%
Management effectiveness
Return on assets (TTM)
-23.51%
Return on equity (TTM)
-49.65%
Valuation
Price to book
1.44
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
-3.01
Free cash flow yield (TTM)
-33.22%
Free cash flow per share (TTM)
-0.615
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
180.28%
3-year earnings per share growth (CAGR)
-29.32%
What the Analysts think about IPSC
Analyst ratings (Buy, Hold, Sell) for Century Therapeutics stock.
Analyst projections of the future price of Century Therapeutics stock.
Bulls say / Bears say
Century says its pre-IND meeting with the FDA produced general alignment on CNTY-813’s nonclinical package, manufacturing tests and proposed Phase 1/2 design. That supports the company’s target of filing the IND in the fourth quarter of 2026, while CNTY-308 is planned to enter the clinic this year. (Century Therapeutics)
CNTY-813 has shown durable glucose control for more than eight months in animal studies, alongside protection from allogeneic immune attack without immunosuppression. Century also reports consistent product quality across independent batches at Phase 1 manufacturing scale, which strengthens the case for an off-the-shelf treatment if the biology translates to humans. (Century Therapeutics, Century Therapeutics)
The company reported $197.2 million of cash, cash equivalents and investments at the end of June and expects this to fund operations into the first quarter of 2029. That should allow Century to reach the CNTY-813 IND, CNTY-308 clinical entry and the expected initial CNTY-813 data without an immediate funding requirement. (Century Therapeutics)
CNTY-813 remains an unproven preclinical programme, with first human safety and efficacy data not expected until the second half of 2027. Conference presentations and animal results do not yet show that the therapy can restore insulin production safely or durably in people. (Alphastreet, Century Therapeutics)
Century has no established product revenue and remains loss-making: its six-month 2026 net loss was reported at $56.2 million, compared with a profit in the prior-year period that included $109.2 million of Bristol Myers Squibb collaboration revenue. The business therefore depends on its pipeline and cash balance rather than commercial sales. (StockTitan)
The stronger balance sheet came partly from a January private placement that raised about $126.4 million but increased the share count, creating dilution for existing holders. Future clinical development may still require more capital if spending rises or milestones slip, despite management’s current runway estimate. (StockTitan, Alphastreet)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
IPSC Financial Performance
Revenues and expenses
IPSC Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing IPSC
Fund name | Fund size | $IPSC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.